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Rap1Statins are widely used to prevent cardiovascular diseases. They are well-tolerated, with side-effects mainly
seen in skeletal muscle. How these side-effects are caused is unknown. We compared isolated primary mouse
skeletal musclemyocytes, C2C12myotubes and liver HepG2 cells to detect differences that could uncover why
statins are toxic in skeletal muscle but less so in the liver. 10 μM simvastatin caused a decrease in
mitochondrial respiration in the primary mouse myocytes and C2C12 myotubes, but had no effect in the
HepG2 cells. Mitochondrial integrity is maintained by multiple signaling pathways. One of these pathways,
Igf-1/Akt signaling, is also heavily implicated in causing statin-induced toxicity by upregulating atrogin-1. We
found that phosphorylated Akt was reduced in C2C12 myotubes but not in HepG2 cells. HepG2 mitochondrial
respiration became susceptible to simvastatin-treatment after Akt inhibition, and mitochondrial respiration
was rescued in Igf-1-treated C2C12 myotubes. These results suggest that disruption of Igf-1/Akt signaling is a
causative factor in simvastatin-induced mitochondrial dysfunction in C2C12 myotubes, whereas HepG2 cells
are protected bymaintaining Igf-1/Akt signaling.We conclude that phosphorylation of Akt is a key indicator of
susceptibility to statin-induced toxicity. How statins can disrupt Igf-1/Akt signaling is unknown. Statins
reduce geranylgeranylation of small GTPases, such as Rap1. Previous studies implicate Rap1 as a link between
cAMP/Epac and Igf-1/Akt signaling. Transient transfection of constitutively active Rap1 into C2C12 myotubes
led to a partial rescue of simvastatin-induced inhibition of mitochondrial respiration, providing a novel link
between signaling and respiration.+41 61 265 45 60.
hl).
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Statins are among themost prescribed drugs inWestern countries.
They reduce morbidity and mortality from coronary heart disease and
mitigate the risk of stroke [1,2]. Their major site of action is the liver,
where they inhibit HMG-CoA (hydroxyl-methyl-glutaryl-coenzyme
A) reductase, the rate-limiting step in cholesterol biosynthesis [3].
Inhibition of this pathway also inhibits various other processes, such
as ubiquinone production and the isoprenylation and N-linked
glycosylation of proteins [4–6]. Altering these processes can reduce
inﬂammation, oxidative stress and platelet adhesion — leading to the
positive effects of statins [7,8].
Statins are generally well tolerated but there are dose-dependent
side-effects, particularly in skeletal muscle where myopathy is seen in
1–5% of patients [9,10]. Their major site of action is the liver, where
adverse effects are rare — elevated liver enzymes are sometimes
observed, but are generally not considered to pose a risk [11,12]. We
have previously shown that the human liver HepG2 cell line is notsusceptible to simvastatin toxicity, and consider this a viable model to
uncover mechanisms of resistance to simvastatin-induced toxicity [6].
Two possible mechanisms of toxicity involve disrupting mitochondrial
health, and upregulating atrophy-inducing proteins [13,14].
Studies in various tissues show that statins can affect the
mitochondria directly, via inhibition of the respiratory chain complexes,
or indirectly via lowering of ubiquinone levels [15,16]. We have already
shown that statins can alter mitochondrial function in skeletal muscle
[13]. It is not known whether statins can affect mitochondrial
respiration in liver cells. We aim to check for any differences between
mitochondrial respiration in C2C12 myotubes and liver HepG2 cells.
Mouse C2C12myotubes are a well-established in vitromodel of skeletal
muscle [6]. Uncovering differences could provide key insights intowhat
makes certain cell lines resistant to statin toxicity whereas other cell
lines are susceptible.
Mitochondrial health is maintained, part, by multiple signaling
pathways [17–19]. Some groups have suggested that impairment in
cell signaling is a major cause of statin-induced myotoxicity [20–22].
One pathway of great interest is the Igf-1/Akt pathway. It is already
known that this pathway is integral to mitochondrial health, and its
impairment has also been implicated as a contributing factor in statin
toxicity [23–26]. We therefore aim to discover whether any potential
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tubes and HepG2 cells can be explained by differences in Igf-1/Akt
signaling.
Baviera et al. suggest that a geranylgeranylated protein, Rap1,
could potentiate Igf-1/Akt signaling [27]. We therefore aim to express
constitutively active Rap1 in C2C12 myotubes to discover whether it
can rescue the myotubes from simvastatin-induced mitochondrial
toxicity. This would increase our knowledge of how simvastatin leads
to mitochondrial toxicity, and how it can affect signaling through the
Igf-1/Akt pathway. Igf-1/Akt signaling is also vital in protecting
skeletal muscle from atrophy, and statin-induced reductions in
signaling lead to an increase in levels of the atrophy-inducing protein
atrogin-1 in skeletal muscle [14]. This increase in atrogin-1 levels is
reversible by the addition of compounds leading to geranylgeranyla-
tion (such as geranylgeranyl pyrophosphate, GGPP) [28]. We will
therefore investigate if expression of constitutively active Rap1 can
prevent the upregulation of atrogin-1 in C2C12 myotubes.
These experiments will increase our understanding of how
statins lead to mitochondrial toxicity, the role that Igf-1/Akt
signaling plays in that, and whether Rap1 mediates the change in
Igf-1/Akt signaling.
2. Materials and methods
2.1. Chemicals
Simvastatin (Sigma-Aldrich, St. Louis, MO, USA) was converted
into the active acid following the protocol of Bogman et al. [29]. Stock
solutions of 10 and 100 mM simvastatin in DMSO were stored at
−20 °C. The ToxiLight® assay kit LT07-117 was from Lonza (Basel,
Switzerland) and the Pierce BCA protein assay kit from Merck
(Darmstadt, Germany). Antibodies to FoxO1, FoxO3a, Akt and P-Akt
were provided by Cell Signaling Technology (Danvers, MA, USA). The
Alexa Fluor® secondary antibodies were from Invitrogen (Basel,
Switzerland). All other chemicals were supplied by Sigma-Aldrich
(St. Louis, MO, USA), except where indicated.
2.2. Primary neonatal mouse myoblast culture
We took skeletal muscle from the hind limbs of neonatal BL6 mice
(kindly provided by Prof. Daniel Bodmer, University Hospital Basel),
and mouse myoblasts using a protocol modiﬁed from Springer et al.
[30]. Brieﬂy, we digested the skeletal muscle with sequential
trypsinization and trituration. We plated the cells for an hour, during
which the non-myocytes adhered to the plate, and collected the
enriched suspension of myocytes. Myocytes were then suspended in
Ham's F10 medium supplemented with 20% FBS, 2% L-glutamine, 1%
bicarbonate and 1% pen/strep. We added 2 ng/ml bFGF to prevent the
proliferation of non-myocytes. The myoblasts were seeded at a
density of 5000 cells per well of a 96-well plate coated with collagen I.
After 24 h, the concentration of bFGF was increased to 5 ng/ml.
Differentiation was induced by changing to Ham's F10 medium
containing 5% horse serum.
2.3. Cell culture
C2C12myoblasts were from the American Type Culture Collection.
We grew the myoblasts in Dulbecco modiﬁed Eagle's medium
(DMEM) high-glucose medium (4.5 g/l) containing 10% FBS and
5 mMHEPES. Themyoblasts were seeded at 150,000 cells per well in a
6-well plate (or equivalent), and grown for 3 days to achieve
conﬂuence. We induced the myoblasts to differentiate into myotubes
using a medium containing 2% horse serum. The myotubes were fully
differentiated after 3 days, after which treatment occurred for 6 h. We
added simvastatin at a concentration of 10 μM and other compoundsat the concentrations indicated. DMSO was used as a control; its
concentration was always 0.1%.
The human liver HepG2 cell line was kindly provided by Prof.
Dietrich von Schweinitz (University Hospital Basel, Switzerland). We
grew the HepG2 cells in DMEM low glucose (1 g/l) containing 10%
FBS, 1% HEPES and 1% non-essential amino acids. We seeded 500,000
cells per well in a 6-well plate (or equivalent). Cells were grown for
1 day, and then treated with the relevant compounds for 24 h.
Both cell lines were grown in a humidiﬁed incubator with 5% CO2
at 37 °C.
2.4. Transfection of C2C12 myoblasts
The pEGFP-C3 plasmid (Clontech, CA, U.S.A.) containing constitu-
tively active Rap1, and the empty plasmid,were kindly provided by Prof.
Mark R. Philips (New York University School of Medicine). C2C12
myoblasts were seeded as before, and grown for 1 day, before
transfection using Lipofectamine 2000 (Invitrogen, CA, U.S.A.). Cells
were then allowed to grow as normal, and differentiate into myotubes.
Approximately equal numbers of GFP-expressing myotubes were
obtained with both plasmids.
2.5. Detection of apoptosis after simvastatin treatment
We used an in situ apoptosis detection kit for Annexin V binding
and propidium iodide (PI) staining (Vybrant™ Apoptosis Assay Kit #2,
from Invitrogen). After incubation with simvastatin, we stained
detached cells with 5 μl Annexin V-AlexaFluor 488 and 1 μl PI (ﬁnal
concentration 1 μg/ml) in Annexin V buffer as per the kit protocol. The
samples were incubated for 15 min and analyzed by ﬂow cytometry,
using a DAKO Cyan cytometer.
2.6. Measurement of mitochondrial membrane potential
We used tetramethylrhodamine, ethyl ester, perchlorate (TMRE;
Invitrogen) to detect changes in mitochondrial membrane potential
(ψm) [31]. Cells were incubated with simvastatin, then detached and
incubatedwith 100 nM TMRE for 30 min at 37 °C and 5% CO2.We used
a Live/Dead® Near-IR Dead Cell stain kit from Invitrogen to exclude
dead cells. Cells were analyzed via ﬂow cytometry with a DAKO Cyan
cytometer. The mitochondrial uncoupler FCCP (10 μM) acted as a
positive control.
2.7. Confocal microscopy
C2C12 myotubes were grown in Lab-Tek microscopy chambers
(Nunc, NY, USA) and treated with simvastatin for 6 h. The cells were
ﬁxed with 4% PFA, permeabilized with 0.2% Triton-X and then labeled
with the appropriate antibody. We used DAPI to stain nuclei. We used
a Zeiss LSM 710 confocal microscope to take the images, and Zen
software to process them. The software quantiﬁed the amount of
antibody staining that co-localized with the DAPI nuclear stain.
2.8. Measurement of oxygen consumption
We measured intact cellular respiration with a Seahorse XF24
analyzer (Seahorse Biosciences, North Billerica, MA, USA). HepG2 cells
and C2C12 myotubes were grown in Seahorse XF 24-well cell culture
microplates 250 μl growth medium. We treated the cells with
simvastatin and other relevant compounds for the times indicated,
and then replaced the medium with 750 μl unbuffered medium. Cells
were equilibrated to the unbuffered medium for 45 min at 37 °C in a
CO2-free incubator, before being transferred to the XF24 analyzer. We
measured basal oxygen consumption (OCR), and then sequentially
injected 1 μM oligomycin, FCCP (1 μM for the HepG2 cells, and 10 μM
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rotenone to assess maximal oxidative capacity.2.9. Isolation of mitochondria
We seeded 2.7 million C2C12 myoblasts in a T175 ﬂask, and
allowed them to differentiate. We isolated mitochondria with the
technique of Hornig-Do et al. that has been commercialized by
Miltenyi Biotec (Germany) [32]. After enrichment, the mitochondria
were washed and resuspended in Miltenyi storage buffer, and kept on
ice until use. We measured protein concentration with a BCA kit, and
averaged a yield of 300 μg mitochondrial protein per T175 ﬂask of
differentiated myotubes.2.10. Immunoblotting
After treatment, we lysed the cells and collected total cell protein
as described previously. We separated 15 μg protein on a 4–12%
gradient gel (Invitrogen, CA, U.S.A.), transferred them to polyvinyli-
dendiﬂuoride membranes, and probed with the relevant antibody (all
used at a 1:1000 dilution). Peroxidase-labeled anti-rabbit antibody,
and chemiluninescence substrate (GE Healthcare) were used for
analysis.2.11. Atrogin-1 mRNA expression
C2C12 myotubes were treated as described. RNA was extracted
and puriﬁed using the Qiagen RNeasy mini extraction kit, with a DNA
digest step to ensure pure RNA. We synthesized cDNA using the
Qiagen omniscript system, and used 10 ng cDNA for quantitative RT-
PCR.We used SYBR green with primers speciﬁc for atrogin-1 (forward
primer: 5′-GAAGACCGCTACTGTGGAA-3′; reverse primer: 5′-
ATCAATCGCTTGCGGATCT-3′). Relative quantities of speciﬁcally am-
pliﬁed cDNA were calculated with the comparative-threshold cycle
method. GAPDH acted as endogenous reference (forward primer: 5′-
CATGGCCTTCCGTGTTCCTA-3′; reverse primer: 5′-CCTGCTTCAC-
CACCTTCTTGA-3′), and no-template and no-reverse-transcription
controls ensured non-speciﬁc ampliﬁcation could be excluded.Fig. 1. Effect of simvastatin on mitochondrial ψm in HepG2 cells and C2C12 myotubes.
Cells were incubated with DMSO or 10 μMsimvastatin. (a) HepG2 cells were treated for
24 h. C2C12 myotubes were treated for (b) 6 or (c) 24 h. TMRE was used to determine
mitochondrial membrane potential, and Near-IR dye from Invitrogen to exclude dead
cells. FCCP was added to one of the DMSO samples to act as a positive control.
The results are means of four independent experiments carried out in triplicate.
*pb0.05 and **pb0.01 versus control.2.12. Statistical analysis
All results are expressed as mean±SD and evaluated with
Student's t-test, where p values of b0.05 were considered signiﬁcant.
We performed the calculations using SPSS.3. Results
3.1. Mitochondrial membrane potential (ψm) is impaired by simvastatin
in C2C12 myotubes but not in HepG2 cells
We previously showed that 10 μM simvastatin is toxic to C2C12
myotubes, but not to HepG2 cells [6]. We now determined whether
there is a difference in the effects on mitochondria. The mitochondrial
ψm is a reliable indicator of mitochondrial health, and it was not
altered in HepG2 cells treated with 10 μM simvastatin for up to 24 h
(Fig. 1a). C2C12 mitochondrial ψm was not reduced after 6 h
treatment with 10 μM simvastatin (Fig. 1b), but had signiﬁcantly
reduced by 11.5% (pb0.05, compared to control) by 24 h treatment
(Fig. 1c). We therefore only treated HepG2 cells for 24 h for the
following experiments, and used both a 24 h treatment and earlier 6 h
treatment to assess toxic mechanisms in C2C12 myotubes.3.2. Simvastatin reduces oxygen consumption in intact C2C12 myotubes,
but not in HepG2 cells
To delve deeper into how simvastatin affects C2C12 mitochondria,
we used a XF24 analyzer to determine changes in OCR in simvastatin-
treated intact C2C12 myotubes and HepG2 cells. OCRs provided a
measurement of the activity of the electron transport chain (ETC).
Oxygen consumption was unaltered after 24 h treatment with 10 μM
simvastatin in HepG2 cells (Fig. 2a). After only 6 h treatment with
10 μM simvastatin in C2C12 myotubes, baseline OCR values were
already signiﬁcantly reduced by 24.2% (pb0.01 compared to control;
Fig. 2b). The OCR reduction with 10 μM simvastatin was still evident
after 24 h treatment (data not shown). FCCP was added to the cells to
determine maximum respiration. The maximum respiration was not
reduced in C2C12myotubes treated with 10 μM simvastatin for 6 h, or
HepG2 cells treated for 24 h.
Fig. 2. Effect of simvastatin on oxygen consumption in intact HepG2 cells, C2C12myotubes and isolated mouse leg myotubes. Cells were incubated with DMSO (blues lines) or 10 μM
(red lines) simvastatin. The XF24 analyzer was used to take measurements. OCRs are shown for (a) 24 h treatment in HepG2 cells, (b) 6 h treatment in C2C12myotubes and (c) 24 h
treatment in isolated mouse leg myotubes. 1 μM oligomycin, FCCP (1 μM for the HepG2 cells, and 10 μM for the C2C12 myotubes and isolated mouse leg myotubes), and 1 μM
rotenone were added at the indicated points. Results are indicative of three independent experiments. *pb0.05 versus control.
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We also determined the OCRs in primary mouse myotubes treated
with 10 μM simvastatin to conﬁrm our in vitro studies. The primary
myotubes showed a similar reduction in OCR to the C2C12 myotubes,
but only after 24 h treatment (by 25.4%, pb0.01; Fig. 2c). This offers
further evidence that simvastatin impairs skeletal muscle mitochon-
drial function.3.4. Oxygen consumption is also reduced in mitochondria isolated from
C2C12 myotubes
We isolatedmitochondria fromC2C12myotubes treatedwith 10 μM
simvastatin, to fully conﬁrm our results. State II (absence of exogenous
ADP), and state III (presence of exogenous ADP) respiration was
measured on the XF-24 analyzer. No changes in respiration were
observed using glutamate/malate/pyruvate as substrates (data not
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respiration were signiﬁcantly reduced in mitochondria isolated from
C2C12 myotubes treated with 10 μM simvastatin for 6 h (by 13.4%
pb0.01 and 12.2% pb0.01, respectively; Fig. 3).
3.5. Statin-treatment leads to a decrease in Akt phosphorylation in
C2C12 myotubes, but not in HepG2 cells
Statins are widely reported to affect the Igf-1/Akt signaling
pathway. This pathway is also important in maintaining mitochon-
drial health—we therefore investigated if differences in this pathway
could explain the differing susceptibility to simvastatin in HepG2 cells
and C2C12 myotubes. HepG2 treated with 10 μM simvastatin for 24 h
saw no change in Akt phosphorylation (Fig. 4a). C2C12 myotubes had
a reduced level of Akt phosphorylation after 6 h treatment with 10 μM
simvastatin (C2C12-mock; Fig. 4b).
3.6. Inhibiting Akt leads to toxicity and inhibition of the ETC in
simvastatin-treated HepG2 cells
We inhibited Akt in HepG2 cells using the speciﬁc inhibitor X from
Sigma. We conﬁrmed inhibition of Akt phosphorylation by immuno-
blotting (Fig. 4a), and also showed that Akt remains unphosphory-
lated when HepG2 cells are treated with 10 μM simvastatin and 5 μM
inhibitor X (Fig. 4a). Coincubation of 10 μM simvastatin with 5 μM
inhibitor X also increased the number of apoptotic HepG2 cells
(Fig. 4c), and reduced basal mitochondrial oxygen consumption
(Fig. 4d).
3.7. Activation of the Igf-1/Akt pathway rescues C2C12 myotubes from
simvastatin-induced mitochondrial impairment
It is well recorded that Igf-1 can rescue skeletalmuscle from statin-
induced damage, so we investigated whether Igf-1 could also rescue
mitochondrial respiration in C2C12 myotubes. We used a 24 h
treatment time, as there was no change in the number of apoptotic
cells after 6 h treatment with 10 μM simvastatin. Myotubes treated
with 10 μM simvastatin showed a signiﬁcant increase in the number
of early apoptotic cells when compared to DMSO control (by 2.43-
fold, pb0.05; Fig. 4e). Co-incubation of 10 ng/ml Igf-1 with 10 μM
simvastatin led to the expected reduction in the number of apoptotic
C2C12 myotubes (reduced 2.72-fold compared to 10 μM simvastatin
treatment, pb0.05; Fig. 4e). The coincubation of 10 ng/ml Igf-1 withFig. 3. Effect of simvastatin on oxygen consumption in mitochondria isolated from C2C12 my
for 6 h, mitochondria isolated, and the XF24 analyzer was used to measure oxygen consump
independent experiments carried out in quintuplicate. **pb0.01 versus DMSO control.10 μM simvastatin also increased mitochondrial respiration in C2C12
myotubes after 24 h treatment (Fig. 4f).
3.8. Constitutively active Rap1 also partially rescues C2C12 myotubes
from simvastatin-induced mitochondrial toxicity
We decided to further investigate how simvastatin could lead to
inhibition of the Igf-1/Akt pathway, and lead to the reduction in
mitochondrial respiration. Previous work by Baviera et al. suggests
that Rap1 could link cAMP signaling to Igf-1/Akt signaling [27]. Our
own lab has also already shown that simvastatin reduces Rap1
prenylation. We hypothesized that reduction in Rap1 activity could
therefore lead to a reduction in signaling through the Igf-1/Akt
pathway. We therefore transiently expressed constitutively active
Rap1in C2C12 myotubes (C2C12-Rap1) to discover whether it could
rescue mitochondrial respiration after treatment with 10 μM simva-
statin. Mock-transfected (C2C12-mock) and pEGFP-transfected
(C2C12-pEGFP) myotubes acted as controls. C2C12-mock and
C2C12-pEGFP myotubes showed the expected decrease in OCR after
treatment with 10 μM simvastatin (by 37.1% and 33% respectively;
Fig. 5). C2C12-Rap1 myotubes had partially rescued mitochondrial
respiration when treated with 10 μM simvastatin for 6 h (a decrease
of only 16.1%; Fig. 5). This suggests that Rap1 could play a role in
mitochondrial health, and that its dysregulation may be an important
stage in simvastatin-induced myotoxicity.
3.9. Constitutively active Rap does not prevent the transcription of
atrogin-1
Dysregulation of the Igf-1/Akt pathway is known to be a key step in
the induction of atrophy via reduction of Akt phosphorylation,
translocation of the Foxo transcription factors to the nucleus and
transcription of the E3 ubiquitin ligase atrogin-1. Previous studies
show that atrogin-1 transcription is increased after statin treatment,
and that atrogin-1 knockout zebraﬁsh are resistant to statin-induced
myopathy— offering strong evidence that atrogin-1 is a key regulator
of statin-induced myopathy. We therefore investigated whether Akt
phosphorylation, Foxo nuclear translocation and atrogin-1 expression
are altered in C2C12-Rap1 myotubes.
C2C12-mock, C2C12-pEGFP and C2C12-Rap1 myotubes all showed
reduced levels of phosphorylated Akt after simvastatin treatment
(Fig. 4b). C2C12-mock, C2C12-pEGFP and C2C12-Rap1 myotubes
showed no increase in Foxo1 nuclear translocation when treated
with 10 μM simvastatin (Fig. 6a). An increase in Foxo3a nuclearotubes. Cells were incubated with DMSO (black bars) or 10 μM simvastatin (white bars)
tion at state II and state III with succinate as the substrate. Results are indicative of four
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mock and C2C12-pEGFP myotubes (Fig. 6b). This increase in Foxo3a
nuclear translocation was not observed in C2C12-Rap1 myotubes
treated with 10 μM simvastatin (Fig. 6b).
C2C12-mock and C2C12-pEGFP myotubes treated with 10 μM
simvastatin showed the expected increase in atrogin-1 transcription
(Fig. 6c). The reduction in nuclear Foxo3a in 10 μM simvastatin-
treated C2C12-Rap1 myotubes did not lead to a decrease in atrogin-1
transcription.
4. Discussion
Statins are widely reported to cause side-effects in skeletal muscle,
ranging from mild weakness to severe rhabdomyolysis [33–35]. Their
major site of action is the liver, where they are well-tolerated and not
toxic. Raised liver enzyme levels are sometimes observed, but they are
not thought to be a risk [11,12]. We have previously shown
differences in cholesterol metabolism between liver HepG2 cells and
skeletal muscle C2C12 myotubes [6]. Other studies show that statins
are mitochondrial toxins, and that reduction in mitochondrial
respiration may be a contributing factor to skeletal muscle myopathy
[13,36,37]. We have expanded on these studies by showing that
simvastatin signiﬁcantly reduces oxygen consumption in C2C12
myotubes, but has no effect on oxygen consumption in simvastatin-
treated HepG2 cells. This result complements the previous studies,
and suggests that mitochondrial health is an important indicator of
susceptibility to simvastatin in skeletal muscle. The 10 μM concen-
tration of simvastatin that we used is higher than would be expected
in the plasma of patients, where values do not exceed 1 μM. However,
localized concentrations could be higher than the observed plasma
levels, as explained above, especially when combined with inhibitors
of cytochrome P450 or OATP1B1 [38].
Numerous signaling pathways are known to be important in
maintaining mitochondrial health, and statins are also known to
dysregulate a wide range of signaling pathways such as AMPK, JNK
and Igf-1 signaling [39–41]. We therefore decided to investigate
whether differences in cell signaling could explain the difference in
mitochondrial respiration in simvastatin-treated HepG2 cells and
C2C12 myotubes. We chose the Igf-1/Akt signaling pathway as it is
both well-described to be altered by statin treatment in muscle and
play a role in mitochondrial maintenance [23–26].
We observed a key difference in phosphorylation state of Akt
between the two cell lines: Akt was dephosphorylated in simvastatin-
treated C2C12 myotubes, whereas simvastatin-treated HepG2 cells
showednochange inAkt phosphorylation. This is theﬁrst study to show
no change in Akt phosphorylation after simvastatin treatment, although
a previous study does show reduced Akt phosphorylation in
pravastatin-treated HepG2 cells [42]. The decrease in phosphorylated
Akt in simvastatin-treated C2C12myotubes complements the results of
Hanai et al. that show lovastatin decreases phosphorylated Akt in C2C12
myotubes [28]. Further weight is added by the study of Mallinson et al.,
who saw similar reductions in Akt phosphorylation in simvastatin-
treated Wistar rats [43].
This difference could reﬂect a difference in the activity of the Igf-1/Akt
signaling pathway in the two cell lines, as Akt phosphorylation is
essential to its activity, and points to a potential explanation to why
simvastatin is toxic to C2C12 myotubes but not to HepG2 cells:Fig. 4. The inﬂuence of Igf-1/Akt signaling on simvastatin-induced mitochondrial toxicity in
HepG2 cells treated for 24 h with 10 μM simvastatin and/or 5 μM Akt inhibitor X, and (b) tr
loading control. The results are indicative of three independent experiments. (c) Annexin V
and analyzed by ﬂow cytometry. The bars show the ratio of late apoptotic cells relative to D
comparison of OCRs in HepG2 cells treated with 10 μM simvastatin and/or 5 μM Akt inh
quintuplicate. (e) Annexin V/PI analysis of C2C12 myotubes treated with 10 μM simvastatin
apoptotic cells relative to DMSO, and are averages of four independent experiments carrie
simvastatin and/or 10 ng/ml Igf-1. The results are the means of four independent experimen
simvastatin.simvastatin-induced toxicity is dependent on Akt maintaining mito-
chondrial function.
To test our theory, we inhibited Akt activity in HepG2 cells, and
activated Akt in C2C12myotubes. Coincubation of simvastatin with Akt
inhibitor X in HepG2 cells led to a lowering ofmitochondrial respiration
and cell viability. This suggests that the ability of HepG2 cells to increase
Akt phosphorylation upon simvastatin-treatment is one mechanism by
which they are protected from toxicity. It also points to the
maintenance of mitochondrial respiration playing an important role
in protecting HepG2 cells after simvastatin-treatment. Coincubation of
C2C12 myotubes with simvastatin and Igf-1 had the expected effect of
rescuing the cells from apoptosis, and also reinstated mitochondrial
respiration. This conﬁrms the previous studies describing the impor-
tance of Igf-1/Akt signaling in statin-induced myotoxicity, and adds to
this knowledge by showing that Igf-1/Akt signaling can rescue
mitochondrial function in simvastatin-treated cells [14,28]. Although
we did not perform activity assays on the complexes of the
mitochondrial respiratory chain, the fact that Igf-1 rescued mitochon-
drial respiration in C2C12myotubes implies that direct inhibition of the
complexes may not be a relevant concern as Igf-1 is not known to bind
to complexes of the ETC (although no studies have investigated
whether Igf-1 could inhibit transport of simvastatin in mitochondria —
which would not rule out direct inhibition).
It is so far unknown how statins can reduce Igf-1/Akt signaling and
lead to toxicity. Previous work, including studies from our own lab,
shows that statins can decrease the production of various interme-
diates in the cholesterol production pathway [4–6]. These interme-
diates, such as ubiquinone, geranylgeranyl pyrophosphate (GGPP)
and dolichol, are important in a wide-range of cellular processes
[5,44,45]. GGPP is important for the geranylgeranylation of proteins,
and many geranylgeranylated proteins are required for cell signaling.
Our previous work shows that Rap1, a small GTPase, has reduced
geranylgeranylation after simvastatin treatment in C2C12 myotubes [6].
Other groups show that Rap1 potentiates Igf-1 signaling, and Baviera et al.
have postulated that Rap1 links cAMP signaling to Igf-1/Akt signaling [27].
On this evidence,wequeriedwhether it is thedisruptionof Rap1 inC2C12
myotubes that leads to a dysregulation of mitochondrial respiration after
simvastatin-treatment.
We transfected constitutively active Rap 1 into C2C12 myotubes
(C2C12-Rap1), and witnessed a partial rescue of mitochondrial
respiration after simvastatin treatment compared to C2C12-mock
and C2C12-pEGFP myotubes. This implies that Rap1 activity is
important in maintaining mitochondrial function. This complements
previous work by Qiao et al. showing that Epac, an activator of Rap1, is
partially located in the mitochondria [46]. Others also show that Rap1
can be found in mitochondria [47,48]. cAMP is also located in
mitochondria, and thought to regulatemitochondrial function [49,50].
Our data adds to this knowledge by offering further evidence of the
importance of Rap1 to mitochondrial health. Our data also provides
evidence that simvastatin exerts its deleterious effects on C2C12
myotube mitochondria via impairment of Rap1.
Our results do not, however, point to Rap1 activating the Igf-1/Akt
pathway. Although we saw a decrease in nuclear Foxo3a, we saw no
increase inAktphosphorylationordecrease in atrogin-1 transcription in
simvastatin-treated C2C12-Rap1 when compared to C2C12-mock or
C2C12-pEGFP myotubes. This suggests that Rap1 protects the mito-
chondria via a non-Igf-1/Akt mechanism. When taken with our dataHepG2 cells and C2C12 myotubes. Immunoblots for total and phosphorylated Akt in (a)
ansfected C2C12 myotubes treated for 6 h with 10 μM simvastatin. Actin was used as a
/PI analysis of HepG2 cells treated with 10 μM simvastatin and/or 5 μM Akt inhibitor X,
MSO, and are averages of four independent experiments carried out in triplicate. (d) A
ibitor X. The results are the means of four independent experiments carried out in
and/or 10 ng/ml Igf-1, and analyzed by ﬂow cytometry. The bars show the ratio of early
d out in triplicate. (f) A comparison of OCRs in C2C12 myotubes treated with 10 μM
ts carried out in quintuplicate. *pb0.05 versus DMSO control, and ‡pb0.05 versus 10 μM
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Fig. 5. The effect of expressing constitutively active Rap1 on mitochondrial toxicity in
C2C12 myotubes. C2C12-mock, C2C12-pEGFP and C2C12-Rap1 myotubes were treated
with DMSO or 10 μMsimvastatin for 6 h. OCRwasmeasured on a XF24 analyzer. Results
are indicative of three independent experiments carried out in quintuplicate. *pb0.05
versus C2C12-mock.
2086 P.J. Mullen et al. / Biochimica et Biophysica Acta 1813 (2011) 2079–2087showing that Igf-1 can rescue simvastatin-induced mitochondrial
impairment, our results point to multiple pathways having a role in
both inducing, and protecting from, toxicity.Fig. 6. The effect of expressing constitutively active Rap1 on atrogin-1 induction in
C2C12 myotubes. (a) Co-localization of Foxo1 with nuclei. Results are the mean of 3
independent experiments. (b) Co-localization of Foxo3a with nuclei. (c) Atrogin-1
mRNA levels were alsomeasured in transfected C2C12myotubes. The results are means
of three independent experiments. *pb0.05 versus DMSO control.How simvastatin can impair the Igf-1/Akt pathway is still unknown,
but Rap1 may still be a key player. It may be that the level of
constitutively active Rap1was not high enough to activate the pathway.
Our transfection efﬁciency was only 30%, whichmay be high enough to
rescuemitochondrial respirationbut not rescueAkt signaling.Weaim to
further investigate the role of Rap1 in the Igf-1/Akt signalingpathwayby
increasing this efﬁciency.
Our data has, for the ﬁrst time, provided a potential explanation for
the difference in susceptibility to toxicity between liver HepG2 cells
and skeletal muscle C2C12 myotubes. The effect of statins on Akt
phosphorylation is well-reported, but this is the ﬁrst study providing
evidence for differing Akt phosphorylation states predisposing cells to
simvastatin-induced toxicity. Also, although preliminary, the ability of
Rap1 to restore mitochondrial respiration in C2C12 myotubes
provides an important link between cellular metabolism and
signaling, and a potential partial explanation for simvastatin-induced
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